Growth prospects that even some Big Pharmas may envy
16/02/26 -"While we have raised our target price, the upside in Sandoz remains limited. Sandoz’s shares are valued at a massive premium to most of its listed peers, and this is why we consider ‘capitalising on ..."
Pages
51
Language
English
Published on
16/02/26
You may also be interested by these reports :
06/03/26
We have incorporated the 2025 reported figures and added a new forecast year (2028) to our model. Consequently, we have reduced the out-year sales ...
05/03/26
The Q4 results fell somewhat short of expectations, as Life Science and Healthcare witnessed decent growth, whereas the quarter was tough for ...
05/03/26
Who would have believed that amongst the star-studded European pharma names, the tiny (in market cap terms, relative to Big Pharmas) Faes Farma (ADD; ...
04/03/26
The Q4 results exceeded expectations, with Crop Science being a key top-line driver. Adjusted EBITDA declined for all three divisions. While the 2026 ...